Family Medicine pp 1087-1094 | Cite as


  • Louise S. Acheson
  • Kurt C. Stange


Osteoporosis is a condition of reduced bone density and increased susceptibility to fractures without abnormal mineralization of bone matrix.1 The World Health Organization (WHO) defines osteoporosis as the presence of a bone mineral density (BMD) at least 2.5 standard deviations below the mean BMD for young adults.2 Osteoporosis affects an estimated 20 million to 25 million people in the United States, particularly postmenopausal women and the elderly of both sexes.3 Its most common serious manifestations are fractures of the hip, forearm, and vertebrae. Measures taken at several critical periods during the life cycle, especially childhood, the climacteric, and old age, have the potential to prevent osteoporotic fractures. Therefore family physicians are in a key position for preventing and treating this disease.


Bone Mineral Density Bone Mass Osteoporotic Fracture Calcium Intake Quantitative Compute Tomography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Am J Med 1991;90:107–10.CrossRefGoogle Scholar
  2. 2.
    World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. WHO Techn Rep Ser 1994;No. 843:1–6.Google Scholar
  3. 3.
    Nevitt MC. Epidemiology of osteoporosis. Rheum Dis Clin North Am 1994;20:535–59.PubMedGoogle Scholar
  4. 4.
    Lufkin EG, Zilkoski M. Diagnosis and management of osteoporosis. American Academy of Family Physicians, Kansas City, MO: American Academy of Family Physicians, 1996. American Family Physician Monograph No. 1.Google Scholar
  5. 5.
    Mundy GR. Peptides and growth regulatory factors in bone. Rheum Dis Clin North Am 1994;20:577–88.PubMedGoogle Scholar
  6. 6.
    Jackson JA, Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology, and prevention. Medicine (Baltimore) 1990; 69:137–52.Google Scholar
  7. 7.
    Christiansen C, editor. Proceedings of a symposium: consensus development conference on osteoporosis. Am J Med 1991;91 Suppl 5B:1S-68S.CrossRefGoogle Scholar
  8. 8.
    Melton LJ III, Eddy DM, Johnston CC Jr. Screening for osteoporosis. Ann Intern Med 1990;112:516–28.PubMedCrossRefGoogle Scholar
  9. 9.
    Breslau NA. Calcium, estrogen, and progestin in the treatment of osteoporosis. Rheum Dis Clin North Am 1994;20: 691–716.PubMedGoogle Scholar
  10. 10.
    Committee on Nutritional Status During Pregnancy and Lactation, Institute of Medicine, National Academy of Sciences. Nutrition during pregnancy. Washington, DC: National Academy Press, 1990:318–35.Google Scholar
  11. 11.
    Committee on Nutritional Status During Pregnancy and Lactation, Institute of Medicine, National Academy of Sciences. Nutrition during lactation. Washington, DC: National Academy Press, 1991:204–6.Google Scholar
  12. 12.
    Licata AA. Therapies for symptomatic primary osteoporosis. Geriatrics 1991;46:62–7.PubMedGoogle Scholar
  13. 13.
    Wishart JM, Need AG, Horowitz M, et al. Effect of age on bone density and bone turnover in men. Clin Endocrinol (Oxf) 1995;42:141–6.CrossRefGoogle Scholar
  14. 14.
    Orwoll ES, Bliziotes M. Heterogeneity in osteoporosis. Rheum Dis Clin North Am 1994;20:671–83.PubMedGoogle Scholar
  15. 15.
    Banas MP, Kaplan FS, Fallon MD, Haddad JG. Regional migratory osteoporosis: a case report and review of the literature. Clin Orthop 1990;250:303–9.PubMedGoogle Scholar
  16. 16.
    Bauer RL. Assessing osteoporosis. Hosp Pract 1991;26 Suppl 1:23–9.Google Scholar
  17. 17.
    Bouxsein ML, Marcus R. Overview of exercise and bone mass. Rheum Dis Clin North Am 1994;20:787–99.PubMedGoogle Scholar
  18. 18.
    Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis: a comparative study of exercise, calcium supplementation, and hormone-replacement therapy N Engl J Med 1991;325:1189–95.PubMedCrossRefGoogle Scholar
  19. 19.
    Grisso JA, Attie M. Prevention of osteoporotic fractures. In: Lavizzo-Mourey R, Day S, Diserens D, Grisso JA, editors. Practicing prevention for the elderly. Philadelphia: Hanley & Belfus, 1989:107–23.Google Scholar
  20. 20.
    US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins, 1996: 509–16, 829–43.Google Scholar
  21. 21.
    Patel U, Skingle S, Campbell GA, Crisp AJ, Boyle IT. Clinical profile of acute vertebral compression fractures in osteoporosis. Br J Rheumatol 1991;30:418–21.PubMedCrossRefGoogle Scholar
  22. 22.
    Rifat SF, Kiningham RB, Peggs JF. Calcitonin in the treatment of osteoporotic bone pain. J Fam Pract 1992;35:93–6.PubMedGoogle Scholar
  23. 23.
    Avioli LV. Calcitonin therapy in osteoporotic syndromes. Rheum Dis Clin North Am 1994;20:777–85.PubMedGoogle Scholar
  24. 24.
    Taylor AK, Lueken SA, Libanata C, Baylin DJ. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am 1994;20:589–605.PubMedGoogle Scholar
  25. 25.
    Hagiwara S, Yang S, Gluer CC, Bendavid E, Genant HK. Noninvasive bone mineral density measurement in the evaluation of osteoporosis. Rheum Dis Clin North Am 1994; 20:651–65.PubMedGoogle Scholar
  26. 26.
    National Osteoporosis Foundation. Bone densitometry and its use in the diagnosis of osteoporosis. Osteoporosis Clin Updates 1996; l (3):l–4.Google Scholar
  27. 27.
    DATTA: diagnostic and therapeutic technology assessment: measurement of bone density with dual-energy x-ray absorptiometry (DEXA). JAMA 1992; 267: 286–94.CrossRefGoogle Scholar
  28. 28.
    Preventing and treating osteoporosis: what every woman needs to know. Older Women’s League (OWL), 666 11th Street NW, Suite 700, Washington, DC 20001,1994:1–20. Women’s Health Education Series.Google Scholar
  29. 29.
    Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332: 767–73.PubMedCrossRefGoogle Scholar
  30. 30.
    Cummings SR, Browner WS, Ettinger B. Should prescription of postmenopausal hormone therapy be based on the results of bone densitometry? Ann Intern Med 1990;113:565–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Stampfer MJ, Colditz G A. Estrogen replacement therapy and coronary artery disease: a quantitative review of the epidemiologic evidence. Prev Med 1991;20:47–63.PubMedCrossRefGoogle Scholar
  32. 32.
    Rubin SM, Cummings SR. Results of bone densitometry affect women’s decisions about taking measures to prevent fractures. Ann Intern Med 1992;116:990–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Ryan PJ, Harrison R, Blake GM, et al. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 1992;99: 325–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med 1992;327:620–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Optimal calcium intake. NIH consensus statement. 1994, June 6–8;12(4):l-31.Google Scholar
  36. 36.
    Calcium supplements. Med Lett 1989;31:101–3.Google Scholar
  37. 37.
    Laitinen K, Lamberg-Allardt C, Tunninen R, et al. Bone mineral density and abstention-induced changes in bone and mineral metabolism in noncirrhotic male alcoholics. Am J Med 1992;93:642–50.PubMedCrossRefGoogle Scholar
  38. 38.
    Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral content in postmenopausal women with breast cancer. N Engl J Med 1992;326:852–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Ettinger B, Grady D. Maximizing the benefit of estrogen therapy for prevention of osteoporosis. Menopause 1994; 1:19–24.CrossRefGoogle Scholar
  40. 40.
    Watts NB. Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 1994;20:717–31.PubMedGoogle Scholar
  41. 41.
    Liberman UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl Med 1995;333:1437–43.CrossRefGoogle Scholar
  42. 42.
    Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995;99:36–42.PubMedCrossRefGoogle Scholar
  43. 43.
    Tilyard MW, Spears GFS, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357–62.PubMedCrossRefGoogle Scholar
  44. 44.
    Bikle DD. Role of vitamin D, its metabolites, and analogs in the management of osteoporosis. Rheum Dis Clin North Am 1994;20:759–75.PubMedGoogle Scholar
  45. 45.
    Kimmel DB, Slovik DM, Lane NE. Current and investigational approaches for reversing established osteoporosis. Rheum Dis Clin North Am 1994;20:735–50.PubMedGoogle Scholar
  46. 46.
    Riggs BL, Hodgson SF, O’Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Pak CY, Adams-Huet B, Piziak V, et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 1995;123:401–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Sebert JL, Richard P, Mennecier I, et al. Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study. Osteoporos Int 1995;5:108–14.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Louise S. Acheson
  • Kurt C. Stange

There are no affiliations available

Personalised recommendations